WASHINGTON, Sept. 9, 2009 (GLOBE NEWSWIRE) — Finkelstein Thompson LLP is investigating potential shareholder claims arising from the proposed acquisition of Candela Corp. (“Candela” or the “Company”) (Nasdaq:CLZR) by Syneron Medical Ltd. (“Syneron”) (Nasdaq:ELOS). Under the terms of the proposed merger, Candela shareholders will receive 0.2911 shares of Syneron stock for each share of Candela common stock owned. This offer represents $2.84 per share of consideration to be received by the Candela shareholders, for a total consideration of approximately $65 million.
The investigation is focused on the potential unfairness of the proposed merger price and of the process by which the Candela Board of Directors is addressing the offer. The Company’s shares traded at a 52-week high of over $3.00 per share.
If you are interested in discussing your rights as Candela shareholder, or have information relating to this investigation, please contact Finkelstein Thompson’s Washington, DC offices at (877) 337-1050 or by email at firstname.lastname@example.org.
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com.